Cardioprotective lipid and method of use
AssigneeSignpath Pharma, Inc.
InventorsJames McChesney, Annie Bouchard, Saravanan Kappusamy, John Kallikat Augustine, Daniel Emil Levy, Dany Salvail
Life of this patent
Estimating the term…
Abstract
The present invention includes a method of reducing or eliminating a cardiotoxic or cardiopathic effect of one or more active agents comprising: administering to a subject in need thereof an effective amount of one or more lipids that reduce or eliminate the cardiotoxic effect of the one or more active agents, wherein the lipid has formula:
Claims41
A composition comprising a compound of Formula I,
- or a pharmaceutically acceptable salt thereof.
A method of preparing a compound of Formula I
- comprising:
A pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable diluent or carrier
- or a pharmaceutically acceptable salt thereof.
A method of reducing or eliminating one or more of a cardiac channelopathy, cardiac muscle damage, or a condition resulting from the irregularity or alteration in the cardiac pattern, in a human or animal subject, comprising the step of administering to the human or animal subject a composition comprising a compound of Formula I
- or a pharmaceutically acceptable salt thereof.
A method of reducing or eliminating a cardiotoxic or cardiopathic effect of one or more active agents comprising:
- administering to a subject in need of treatment for a disease or disorder one or more one or more active agents that are cardiotoxic;
- and
- providing a combination therapy with an effective amount of one or more lipids that reduce or eliminate the cardiotoxic effect of the one or more active agents, wherein the lipid has formula:
- or a pharmaceutically acceptable salt thereof.
A method of reducing or eliminating a cardiotoxic effect of one or more antiproliferative agents comprising:
- administering to a subject in need of treatment for a proliferative disorder one or more antiproliferative agents that are cardiotoxic;
- and
- providing a combination therapy with an effective amount of one or more lipids that reduce or eliminate the cardiotoxic effect of one or more antiproliferative agents, wherein the lipid has formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.